Navigation Links
European researchers look for new ways to fight multi-drug-resistant bacterial infections
Date:6/25/2009

The Institute of Biotechnology and Biomedicine (IBB) belonging to Universitat Autnoma de Barcelona (UAB) is directing the AntiPathoGN European research project aimed at looking for new drug targets in pathogenic bacteria resistant to multiple antibiotics. To do so a consortium was created by six institutions and firms in Spain, three in Germany, one in France and one in Bulgaria. The project, which will cost approximately 7.7 million euros, will be carried out during four years. The European Union has subsidised the project with six million euros.

In the past decade bacterial resistance to antibiotics has risen significantly whereas in some cases the rise has been dramatic such as in hospital areas. It has reached such a stage that the World Health Organization considers these multi-drug-resistant microorganisms the cause of emerging infectious diseases. Currently a large amount of antibiotics available are not apt for the treatment of resistant pathogens belonging to an important group called gram-negative bacteria. On occasions, the choice narrows down to one drug such as the "last-resort" antibiotic colistin to treat infections caused by the bacteria Pseudomonas aeruginosa or Acinetobacter baumannii. At the same time, the lack of economic benefits has reduced the amount of research pharmaceutical companies dedicate to creating new antibiotics.

Given this situation, the AntiPathoGN project intends to cover the need for more knowledge of the biological processes and cell growth and division mechanisms of four of the most resistant gram-negative bacteria - Pseudomonas aeruginosa, Helicobacter pylori, Acinetobacter baumannii and Escherichia coli. These bacteria cause respiratory, digestive, urinary tract, skin and many other types of infections, and researchers aim to discover new substances which would be effective in fighting against them. The project works with a multidisciplinary approach and includes innovative contributions from the fields of microbiology, proteomics, and computational and structural biology, as well as pharmaceutics.

The AntiPathoGN project is coordinated by Xavier Daura, professor at UAB's Catalan Institute for Research and Advanced Studies (ICREA). Other participating institutes are the Institute for Biomedical Research (IRB Barcelona), the Clinical Foundation for Biomedical Research (Fundaci Clnic per a la Recerca Biomdica- FCRB), and the biotechnology firms Infociencia, Anaxomics Biotech and Microbionta.


'/>"/>

Contact: Maria Jesus Delgado
MariaJesus.Delgado@uab.cat
34-935-814-049
Universitat Autonoma de Barcelona
Source:Eurekalert

Related medicine news :

1. Verizon Private IP Quadruples Network Capacity for Invacares European Operations
2. Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market
3. Chiltern Expands European Operations With a New Office in Belgium
4. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
5. Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors, Finds Frost & Sullivan
6. Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity
7. Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office
8. Cord Blood America Continuing European Expansion
9. EUROPACE 2009, the leading European congress on cardiac arrhythmias and pacing
10. Screening Programs to Drive European GI Videoscope Market Despite Economic Downturn, According to Millennium Research Group
11. Impliant Granted Two New U.S. Patents and Successfully Defends European Patent Opposition Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: